364 filings
Page 3 of 19
8-K
sw4m0vp9231y3rxm7
5 Aug 21
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
7:06am
8-K
8sqd32ajfi4f
3 Aug 21
Departure of Directors or Certain Officers
5:19pm
8-K
2wclst7hck5 xgn5sew
28 Jul 21
BioCryst Appoints Vincent Milano to Board of Directors
7:09am
8-K
3m6odd68r9k
3 Jun 21
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
7:06am
8-K
8fkt9d165r565
26 May 21
Departure of Directors or Certain Officers
4:26pm
8-K
nfc42jsgq 7b0py
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
kw2pue
6 May 21
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
7:09am
8-K
nqx4w4y
30 Apr 21
Regulation FD Disclosure
10:57am
8-K
usato41g3oqs6ow 4wfw
14 Apr 21
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
8:21am
8-K
f9jssmho7
26 Mar 21
Regulation FD Disclosure
2:02pm
8-K
v2b504n m6
22 Mar 21
Regulation FD Disclosure
8:07am
8-K
c3n9fst
18 Mar 21
Regulation FD Disclosure
4:41pm
8-K
iu9tqoa07r2pb
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
rfmzvcz5v 026vvrwm1
25 Feb 21
Regulation FD Disclosure
4:40pm
8-K
3puoa1
25 Feb 21
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
7:05am
8-K
3qysn2l9
3 Feb 21
Regulation FD Disclosure
7:06am
8-K
55vl7ll6ktkmm
22 Jan 21
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
7:12am
8-K
6relcuzn4tjrw ibbp
22 Dec 20
Regulation FD Disclosure
8:16am
8-K
2tyjl3w1im92bq ixt
22 Dec 20
BioCryst Provides Update on Galidesivir Program
7:03am
8-K
s65v2mk id
21 Dec 20
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
7:05am